PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF HIGH-DOSE MITOXANTRONE COMBINED WITH CARBOPLATIN, CYCLOPHOSPHAMIDE, AND AUTOLOGOUS BONE-MARROW RESCUE - HIGH RESPONSE RATE FOR REFRACTORY OVARIAN-CARCINOMA

被引:52
|
作者
STIFF, PJ
MCKENZIE, RS
ALBERTS, DS
SOSMAN, JA
DOLAN, JR
RAD, N
MCCLOSKEY, T
机构
[1] UNIV ARIZONA, DEPT MED, TUCSON, AZ 85721 USA
[2] UNIV ARIZONA, DEPT PHARMACOL, TUCSON, AZ 85721 USA
[3] UNIV ARIZONA, ARIZONA CANC CTR, TUCSON, AZ 85721 USA
[4] LOYOLA UNIV, MED CTR, DEPT OBSTET & GYNECOL, MAYWOOD, IL 60153 USA
关键词
D O I
10.1200/JCO.1994.12.1.176
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To develop an active high-dose chemotherapy regimen for the treatment of ovarian carcinoma. Due to the rapid development of drug resistance, conventional chemotherapy cures only 20% of patients with advanced disease. However, in vitro data demonstrate a steep dose-response curve to a variety of agents, most notably mitoxantrone. Patients and Methods: A phase I study of escalated bolus mitoxantrone (10 to 25 mg/m2 x 3) and cyclophosphamide (30 to 50 mg/kg x 3) with a 5-day infusion of carboplatin (1,500 mg/m2) and an autologous bone marrow transplant (ABMT) was performed. Mitoxantrone pharmacokinetics were performed to document levels required to kill platinum-resistant ovarian carcinoma in vitro. Results: We treated 25 patients; the maximum-tolerated total doses (MTD) were 75 mg/m2 for mitoxantrone, 120 mg/kg for cyclophosphamide, and 1,500 mg/m2 for carboplatin. The dose-limiting toxicity was gastrointestinal, with severe diarrhea, ileus, and resulting sepsis. Transient partial deafness was seen in four patients, and acute renal failure (ARF) occurred in one patient at the first dose level, but was eliminated in subsequent patients with aggressive hydration. There were four early deaths due to ARF (n = 1), Legionella pneumonia (n = 1), and sepsis (n = 2). Peak mitoxantrone levels at the MTD were 623 to 2,810 ng/mL, and the area under the curve (AUC) values of the concentration versus time measurements were 560 to 1,700 ng/mL/h. Of 20 assessable patients, 65% responded, with a 45% complete remission (CR) rate. All six of the assessable patients with ovarian cancer responded: CR in five (83%) and partial remission (PR) in one (17%); the CRs have lasted 7 to 30+ months. Responses were also seen in testicular and breast carcinoma. Conclusion: This regimen was well tolerated at the MTD and appears promising for relapsed/refractory ovarian carcinoma, with mitoxantrone levels achieved that are active in vitro against platinum-resistant ovarian carcinoma cells.
引用
收藏
页码:176 / 183
页数:8
相关论文
共 50 条
  • [21] HIGH-DOSE CARBOPLATIN, CYCLOPHOSPHAMIDE, AND BCNU WITH AUTOLOGOUS BONE-MARROW SUPPORT - EXCESSIVE HEPATIC TOXICITY
    JONES, RB
    SHPALL, EJ
    ROSS, M
    CONIGLIO, D
    AFFRONTI, ML
    PETERS, WP
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 (02) : 155 - 156
  • [22] PHASE-I STUDY OF HIGH-DOSE DIMETHYLBUSULFAN FOLLOWED BY AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN PATIENTS WITH ADVANCED MALIGNANCY
    KANFER, EJ
    PETERSEN, FB
    BUCKNER, CD
    STEWART, P
    STORB, R
    HILL, RS
    APPELBAUM, FR
    CLIFT, RA
    DONEY, KC
    SHULMAN, HM
    THOMAS, ED
    CANCER TREATMENT REPORTS, 1987, 71 (01): : 101 - 102
  • [23] HIGH-DOSE CARBOPLATIN AND MITOXANTRONE WITH AUTOLOGOUS BONE-MARROW SUPPORT IN THE TREATMENT OF ADVANCED BREAST-CANCER
    BROUN, ER
    SLEDGE, GW
    EINHORN, LH
    TRICOT, GJK
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (01): : 9 - 13
  • [24] TREATMENT OF RECURRENT AND REFRACTORY PEDIATRIC SOLID TUMORS WITH HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS BONE-MARROW RESCUE
    GRAHAM, ML
    YEAGER, AM
    LEVENTHAL, BG
    WILEY, JM
    CIVIN, CI
    STRAUSS, LC
    HURWITZ, CA
    DUBOWY, RL
    WHARAM, MD
    COLOMBANI, PM
    ROWLEY, SD
    BRAINE, HG
    SANTOS, GW
    JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (12) : 1857 - 1864
  • [25] DOSE-INTENSIVE CHEMOTHERAPY IN REFRACTORY GERM-CELL CANCER - A PHASE-I/II TRIAL OF HIGH-DOSE CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    NICHOLS, CR
    TRICOT, G
    WILLIAMS, SD
    VANBESIEN, K
    LOEHRER, PJ
    ROTH, BJ
    AKARD, L
    HOFFMAN, R
    GOULET, R
    WOLFF, SN
    GIANNONE, L
    GREER, J
    EINHORN, LH
    JANSEN, J
    JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (07) : 932 - 939
  • [26] PRELIMINARY-RESULTS OF HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE WITH SYNGENEIC OR AUTOLOGOUS BONE-MARROW RESCUE
    LU, C
    BRAINE, HG
    KAIZER, H
    SARAL, R
    TUTSCHKA, PJ
    SANTOS, GW
    CANCER TREATMENT REPORTS, 1984, 68 (05): : 711 - 717
  • [27] A CLINICAL AND PHARMACOLOGICAL STUDY OF HIGH-DOSE MITOZOLOMIDE GIVEN IN CONJUNCTION WITH AUTOLOGOUS BONE-MARROW RESCUE
    MCKEAGE, M
    DADY, P
    CLEAR, M
    MACDONALD, A
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 29 (03) : 201 - 206
  • [29] PHASE-I STUDY OF REPEATED CYCLES OF HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN ADMINISTERED WITHOUT BONE-MARROW TRANSPLANTATION
    NEIDHART, JA
    KOHLER, W
    STIDLEY, C
    MANGALIK, A
    PLAUCHE, A
    ANDERSON, T
    QUENZER, RW
    RINEHART, JJ
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (10) : 1728 - 1738
  • [30] A PHASE-I TRIAL OF HIGH-DOSE DIAZIQUONE AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION - AN ILLINOIS-CANCER-COUNCIL-STUDY
    STIFF, PJ
    MCKENZIE, RS
    POTEMPA, LD
    ALBAIN, K
    KOCH, D
    BRAUD, E
    BANSAL, VK
    WEIDNER, MK
    LANZOTTI, VJ
    CHUN, HG
    JOHNSON, C
    FISHER, RI
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (08) : 1487 - 1494